Which has higher earnings and valuation, CBLL or INFU?

InfuSystem has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CeriBell $89.06M 7.80 -$53.41M -$1.63 N/A InfuSystem $142.40M 1.34 $870K $0.38 24.85

Is CBLL or INFU more profitable?

InfuSystem has a net margin of 1.12% compared to CeriBell's net margin of -63.51%. InfuSystem's return on equity of 2.78% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -63.51% -38.19% -30.92% InfuSystem 1.12% 2.78% 1.41%

Does the media refer more to CBLL or INFU?

In the previous week, CeriBell had 8 more articles in the media than InfuSystem. MarketBeat recorded 9 mentions for CeriBell and 1 mentions for InfuSystem. CeriBell's average media sentiment score of 0.60 beat InfuSystem's score of 0.00 indicating that CeriBell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InfuSystem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor INFU or SGP?

In the previous week, Spyglass Pharma had 4 more articles in the media than InfuSystem. MarketBeat recorded 5 mentions for Spyglass Pharma and 1 mentions for InfuSystem. Spyglass Pharma's average media sentiment score of 0.19 beat InfuSystem's score of 0.00 indicating that Spyglass Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InfuSystem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyglass Pharma 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, INFU or BWAY?

Brainsway has lower revenue, but higher earnings than InfuSystem. InfuSystem is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InfuSystem $142.40M 1.34 $870K $0.38 24.85 Brainsway $56.22M 11.06 $7.57M $0.35 44.27

Is INFU or BWAY more profitable?

Brainsway has a net margin of 15.68% compared to InfuSystem's net margin of 1.12%. Brainsway's return on equity of 12.28% beat InfuSystem's return on equity. Company Net Margins Return on Equity Return on Assets InfuSystem 1.12% 2.78% 1.41% Brainsway 15.68% 12.28% 7.75%

Does the media prefer INFU or BWAY?

In the previous week, Brainsway had 2 more articles in the media than InfuSystem. MarketBeat recorded 3 mentions for Brainsway and 1 mentions for InfuSystem. Brainsway's average media sentiment score of 0.42 beat InfuSystem's score of 0.00 indicating that Brainsway is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InfuSystem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Brainsway 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, INFU or MDXG?

MiMedx Group has higher revenue and earnings than InfuSystem. InfuSystem is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InfuSystem $142.40M 1.34 $870K $0.38 24.85 MiMedx Group $355.17M 1.82 $48.58M $0.04 111.15

Does the media favor INFU or MDXG?

In the previous week, MiMedx Group had 18 more articles in the media than InfuSystem. MarketBeat recorded 19 mentions for MiMedx Group and 1 mentions for InfuSystem. MiMedx Group's average media sentiment score of 0.05 beat InfuSystem's score of 0.00 indicating that MiMedx Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InfuSystem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MiMedx Group 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TCMD or INFU?

In the previous week, Tactile Systems Technology had 2 more articles in the media than InfuSystem. MarketBeat recorded 3 mentions for Tactile Systems Technology and 1 mentions for InfuSystem. Tactile Systems Technology's average media sentiment score of 1.65 beat InfuSystem's score of 0.00 indicating that Tactile Systems Technology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tactile Systems Technology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive InfuSystem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

InfuSystem (INFU) Competitors

$9.44 +0.30 (+3.34%)

As of 10:11 AM Eastern

Compare

INFU vs. CBLL, SGP, BWAY, MDXG, and TCMD

Should you buy InfuSystem stock or one of its competitors? MarketBeat compares InfuSystem with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InfuSystem include CeriBell (CBLL), Spyglass Pharma (SGP), Brainsway (BWAY), MiMedx Group (MDXG), and Tactile Systems Technology (TCMD).

How does InfuSystem compare to CeriBell?

CeriBell (NASDAQ:CBLL) and InfuSystem (NYSE:INFU) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

CeriBell presently has a consensus price target of $22.20, suggesting a potential upside of 21.21%. InfuSystem has a consensus price target of $15.00, suggesting a potential upside of 58.83%. Given InfuSystem's higher probable upside, analysts clearly believe InfuSystem is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, CeriBell had 8 more articles in the media than InfuSystem. MarketBeat recorded 9 mentions for CeriBell and 1 mentions for InfuSystem. CeriBell's average media sentiment score of 0.60 beat InfuSystem's score of 0.00 indicating that CeriBell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InfuSystem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InfuSystem has a net margin of 1.12% compared to CeriBell's net margin of -63.51%. InfuSystem's return on equity of 2.78% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
InfuSystem	1.12%	2.78%	1.41%

CeriBell has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, InfuSystem has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

InfuSystem has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	7.80	-$53.41M	-$1.63	N/A
InfuSystem	$142.40M	1.34	$870K	$0.38	24.85

71.1% of InfuSystem shares are held by institutional investors. 17.7% of CeriBell shares are held by company insiders. Comparatively, 10.8% of InfuSystem shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

InfuSystem beats CeriBell on 10 of the 17 factors compared between the two stocks.

How does InfuSystem compare to Spyglass Pharma?

InfuSystem (NYSE:INFU) and Spyglass Pharma (NASDAQ:SGP) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

In the previous week, Spyglass Pharma had 4 more articles in the media than InfuSystem. MarketBeat recorded 5 mentions for Spyglass Pharma and 1 mentions for InfuSystem. Spyglass Pharma's average media sentiment score of 0.19 beat InfuSystem's score of 0.00 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InfuSystem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

71.1% of InfuSystem shares are held by institutional investors. 10.8% of InfuSystem shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

InfuSystem has a net margin of 1.12% compared to Spyglass Pharma's net margin of 0.00%. InfuSystem's return on equity of 2.78% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
Spyglass Pharma	N/A	N/A	N/A

InfuSystem has higher revenue and earnings than Spyglass Pharma. Spyglass Pharma is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$142.40M	1.34	$870K	$0.38	24.85
Spyglass Pharma	N/A	N/A	N/A	-$6.41	N/A

InfuSystem presently has a consensus price target of $15.00, suggesting a potential upside of 58.83%. Spyglass Pharma has a consensus price target of $45.00, suggesting a potential upside of 96.64%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Spyglass Pharma is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

InfuSystem beats Spyglass Pharma on 8 of the 13 factors compared between the two stocks.

How does InfuSystem compare to Brainsway?

InfuSystem (NYSE:INFU) and Brainsway (NASDAQ:BWAY) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

71.1% of InfuSystem shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 10.8% of InfuSystem shares are held by insiders. Comparatively, 19.0% of Brainsway shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Brainsway had 2 more articles in the media than InfuSystem. MarketBeat recorded 3 mentions for Brainsway and 1 mentions for InfuSystem. Brainsway's average media sentiment score of 0.42 beat InfuSystem's score of 0.00 indicating that Brainsway is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InfuSystem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Brainsway	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InfuSystem presently has a consensus price target of $15.00, suggesting a potential upside of 58.83%. Brainsway has a consensus price target of $15.67, suggesting a potential upside of 1.11%. Given InfuSystem's higher possible upside, equities analysts clearly believe InfuSystem is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Brainsway	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17

InfuSystem has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

Brainsway has lower revenue, but higher earnings than InfuSystem. InfuSystem is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$142.40M	1.34	$870K	$0.38	24.85
Brainsway	$56.22M	11.06	$7.57M	$0.35	44.27

Brainsway has a net margin of 15.68% compared to InfuSystem's net margin of 1.12%. Brainsway's return on equity of 12.28% beat InfuSystem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
Brainsway	15.68%	12.28%	7.75%

Summary

Brainsway beats InfuSystem on 11 of the 17 factors compared between the two stocks.

How does InfuSystem compare to MiMedx Group?

InfuSystem (NYSE:INFU) and MiMedx Group (NASDAQ:MDXG) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

MiMedx Group has higher revenue and earnings than InfuSystem. InfuSystem is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$142.40M	1.34	$870K	$0.38	24.85
MiMedx Group	$355.17M	1.82	$48.58M	$0.04	111.15

In the previous week, MiMedx Group had 18 more articles in the media than InfuSystem. MarketBeat recorded 19 mentions for MiMedx Group and 1 mentions for InfuSystem. MiMedx Group's average media sentiment score of 0.05 beat InfuSystem's score of 0.00 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InfuSystem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiMedx Group	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

71.1% of InfuSystem shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 10.8% of InfuSystem shares are owned by company insiders. Comparatively, 2.5% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

InfuSystem has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

InfuSystem presently has a consensus price target of $15.00, suggesting a potential upside of 58.83%. MiMedx Group has a consensus price target of $8.50, suggesting a potential upside of 91.18%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

MiMedx Group has a net margin of 1.76% compared to InfuSystem's net margin of 1.12%. MiMedx Group's return on equity of 12.09% beat InfuSystem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
MiMedx Group	1.76%	12.09%	9.22%

Summary

MiMedx Group beats InfuSystem on 13 of the 16 factors compared between the two stocks.

How does InfuSystem compare to Tactile Systems Technology?

Tactile Systems Technology (NASDAQ:TCMD) and InfuSystem (NYSE:INFU) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Tactile Systems Technology has a net margin of 5.91% compared to InfuSystem's net margin of 1.12%. Tactile Systems Technology's return on equity of 9.70% beat InfuSystem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tactile Systems Technology	5.91%	9.70%	7.53%
InfuSystem	1.12%	2.78%	1.41%

Tactile Systems Technology has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, InfuSystem has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

83.4% of Tactile Systems Technology shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 2.1% of Tactile Systems Technology shares are owned by company insiders. Comparatively, 10.8% of InfuSystem shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tactile Systems Technology presently has a consensus price target of $38.60, indicating a potential upside of 32.56%. InfuSystem has a consensus price target of $15.00, indicating a potential upside of 58.83%. Given InfuSystem's higher probable upside, analysts plainly believe InfuSystem is more favorable than Tactile Systems Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tactile Systems Technology	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Tactile Systems Technology has higher revenue and earnings than InfuSystem. InfuSystem is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tactile Systems Technology	$329.52M	1.99	$19.09M	$0.88	33.09
InfuSystem	$142.40M	1.34	$870K	$0.38	24.85

In the previous week, Tactile Systems Technology had 2 more articles in the media than InfuSystem. MarketBeat recorded 3 mentions for Tactile Systems Technology and 1 mentions for InfuSystem. Tactile Systems Technology's average media sentiment score of 1.65 beat InfuSystem's score of 0.00 indicating that Tactile Systems Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tactile Systems Technology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
InfuSystem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Tactile Systems Technology beats InfuSystem on 13 of the 17 factors compared between the two stocks.

Get InfuSystem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INFU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INFU vs. The Competition

Export

Metric	InfuSystem	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$190.64M	$9.93B	$6.81B	$23.73B
Dividend Yield	N/A	2.52%	2.59%	4.21%
P/E Ratio	157.46	25.64	282.12	31.30
Price / Sales	1.34	4.72	573.08	165.84
Price / Cash	12.79	26.24	28.60	18.73
Price / Book	3.82	5.21	11.02	4.81
Net Income	$870K	$311.05M	$3.49B	$1.07B
7 Day Performance	0.90%	-0.28%	0.47%	0.60%
1 Month Performance	-7.05%	-0.95%	-4.24%	0.38%
1 Year Performance	65.68%	27.28%	62.63%	20.06%

InfuSystem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INFU InfuSystem	4.0288 of 5 stars	$9.44 +3.3%	$15.00 +58.8%	+60.4%	$190.64M	$142.40M	157.46	410
CBLL CeriBell	2.9458 of 5 stars	$17.89 -2.9%	$22.20 +24.1%	+25.1%	$699.28M	$89.06M	N/A	N/A	News Coverage Upcoming Earnings
SGP Spyglass Pharma	2.7586 of 5 stars	$20.27 +1.2%	$45.00 +122.0%	N/A	$677.69M	N/A	N/A	65	Lockup Expiration
BWAY Brainsway	3.6371 of 5 stars	$16.15 -2.1%	$15.67 -3.0%	+165.6%	$662.13M	$56.22M	46.14	120	Analyst Upgrade Gap Up
MDXG MiMedx Group	2.8994 of 5 stars	$4.32 -0.2%	$8.50 +96.8%	-42.3%	$644.94M	$389.42M	21.60	870	Earnings Report Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:INFU) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InfuSystem (INFU) Competitors

INFU vs. CBLL, SGP, BWAY, MDXG, and TCMD

How does InfuSystem compare to CeriBell?

Summary

How does InfuSystem compare to Spyglass Pharma?

Summary

How does InfuSystem compare to Brainsway?

Summary

How does InfuSystem compare to MiMedx Group?

Summary

How does InfuSystem compare to Tactile Systems Technology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INFU vs. The Competition

InfuSystem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InfuSystem (INFU) Competitors

INFU vs. CBLL, SGP, BWAY, MDXG, and TCMD

How does InfuSystem compare to CeriBell?

Do analysts rate CBLL or INFU?

Does the media refer more to CBLL or INFU?

Is CBLL or INFU more profitable?

Which has more volatility and risk, CBLL or INFU?

Which has higher earnings and valuation, CBLL or INFU?

Do insiders and institutionals have more ownership in CBLL or INFU?

Summary

How does InfuSystem compare to Spyglass Pharma?

Does the media favor INFU or SGP?

Do institutionals & insiders have more ownership in INFU or SGP?

Is INFU or SGP more profitable?

Which has preferable earnings and valuation, INFU or SGP?

Do analysts recommend INFU or SGP?

Summary

How does InfuSystem compare to Brainsway?

Do insiders and institutionals hold more shares of INFU or BWAY?

Does the media prefer INFU or BWAY?

Do analysts recommend INFU or BWAY?

Which has more risk & volatility, INFU or BWAY?

Which has preferable valuation and earnings, INFU or BWAY?

Is INFU or BWAY more profitable?

Summary

How does InfuSystem compare to MiMedx Group?

Which has better valuation & earnings, INFU or MDXG?

Does the media favor INFU or MDXG?

Do insiders and institutionals hold more shares of INFU or MDXG?

Which has more volatility and risk, INFU or MDXG?

Do analysts recommend INFU or MDXG?

Is INFU or MDXG more profitable?

Summary

How does InfuSystem compare to Tactile Systems Technology?

Is TCMD or INFU more profitable?

Which has more volatility & risk, TCMD or INFU?

Do insiders and institutionals believe in TCMD or INFU?

Do analysts prefer TCMD or INFU?

Which has stronger valuation and earnings, TCMD or INFU?

Does the media favor TCMD or INFU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INFU vs. The Competition

InfuSystem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools